Sign Up to like & get
recommendations!
1
Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14102198
Abstract: Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug and thereby limits the clinical application. In…
read more here.
Keywords:
bexarotene;
prediction bexarotene;
bioavailability;
bex ... See more keywords